|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Adventrx Pharmaceuticals Inc., of San Diego, said data collected from its ongoing CoFactor Phase II trial in metastatic colorectal cancer and a recent preclinical study that compared toxicity and antitumor activity of CoFactor used in combination with 5-flourouracil and other agents will support filings with the FDA and European officials to begin late-stage trials. CoFactor is a biomodulator designed to enhance the activity of 5-FU. The data will be presented next week at the American Association for Cancer Research annual meeting in Anaheim, Calif.
o Ambion Diagnostics, of Austin, Texas, a division of Ambion Inc., granted Cepheid Inc., of Sunnyvale, Calif., ...